Sensei Biotherapeutics, Inc. (SNSE)
| Market Cap | 481.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.67M |
| Shares Out | 29.56M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $14.50 |
| Previous Close | $15.74 |
| Change ($) | -1.24 |
| Change (%) | -7.88% |
| Day's Open | 15.89 |
| Day's Range | 13.60 - 16.00 |
| Day's Volume | 266,926 |
| 52-Week Range | 13.60 - 26.50 |
If the insiders are buying, other investors should at least pay attention. These seven stocks are ones to keep an eye on here.
BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation th...
BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation th...
BOSTON & ROCKVILLE, Md.--Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announc...
Sensei Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Sensei Biotherapeutics, a Phase 2 biotech developing bacteriophage-based therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston research and development hub last year, has attracted high-profile investors for its $30 million Seri...
About SNSE
Sensei Biotherapeutics, a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further en... [Read more...]
| Industry Biotechnology | IPO Date Feb 4, 2021 |
| CEO John Celebi | Employees 24 |
| Stock Exchange NASDAQ | Ticker Symbol SNSE |